Oncology

Bone metastases occur in the majority of women with metastatic breast cancer. The results from this study are highly clinically relevant as they demand us to question whether a "one size fits all" bisphosphonate prescription is most efficacious in preventing skeletal related events (SREs). Further prospective study is merited to characterize the optimal use of bisphosphonates in patients who were found to be at highest risk of developing a SRE - persons with bone only disease and/or with osteoporosis. Finally, this study supports current studies investigating the impact of bisphosphonate use in the adjuvant breast cancer setting, as the results may impact these high risk features for developing a SRE upon diagnosis of bone metastases.